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ABSTRACT
Objectives: To determine the level of coagulation factors and inherited inhibitors in 
Fresh Frozen Plasma (FFP) and to evaluate Prothrombin Time and activated partial 
thrombin time in fresh frozen plasma.
Design: Cross-sectional study.
Setting: Jomo Kenyatta University of Agriculture and Technology in Medical Laboratory 
Sciences.
Subjects: Eighteen blood bags collected from voluntary blood donors.
Main outcome measures:Coagulation factors and inhibitors levels, Prothrombin Time 
(PT) and Activated Partial thrombin Time (APTT)remained within the reference range 
requested by quality assurance regulations after three months of storage.
Results: APTT and PT show an increase from baseline to one month then remain 
constant up to three months, while, Fibrinogen, Factor II, Factor V, Factor VII, Factor 
X, Von Willbrand Factor, Protein C and Antithrombin decreased from baseline up 
to three months and then Factor VIII, Factor IX, Factor XI, Factor XII and Protein S, 
remained constant from baseline up to one month and decreased up to three months.
Conclusion: There is good retention of all coagulation factors and inhibitors in plasma 
produced from whole blood within eight hours of collection, stored at minus 18ºC 
for three months.
INTRODUCTION
Coagulation factors are plasma proteins that play 
a major role in blood coagulation process. These 
factors maintain haemostasis balance between 
clotting and anti-clotting (1).Fresh frozen plasma 
(FFP) is indicated for the treatment and prevention 
of bleeding disorders due to deficit in minor or major 
coagulation factors, defective management of massive 
bleedings, liver disease, disseminated intra-vascular 
coagulation or reverse anti-coagulant therapy (2). This 
study is therefore aimed at determining the levels 
of coagulation factors at minus 18ºC temperatures.
 Bleeding disorders due to deficiency of 
coagulation factors VIII and IX known as haemophilia 
A and B respectively, are the common and frequent 
clinical problem; then von Willebrand factor 
deficiency and the other factors rare deficiency come 
on the forth position as stated by World federation 
of haemophilia report on the annual global survey 
2011. They are associated with increased morbidity, 
faster progression to other disease such as anaemia, 
decreased survival time, and increased mortality. 
Factor defect or deficit individuals who are severely 
anaemic experience due to excess bleeding in case of 
trauma or injury, functional impairment, decreased 
sense of wellbeing, and a poorer quality of life. 
For these reasons, it is imperative that clinicians in 
coagulopathy care are prepared to manage bleeding 
disorders related coagulation factors deficiency using 
fresh frozen plasma and factor concentrate where 
they are available and affordable.  Understanding 
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the use and indication of fresh frozen plasma and 
knowing the level of each coagulation factor and 
the level require for plasma to be used for treatment 
purpose, helps to ensure that haemophiliac 
individuals and other patient suffering from bleeding 
disorders due to coagulation factors disorders receive 
appropriate treatment. In Rwanda there are many 
resource limited Referral, District hospitals and 
health centres laboratories, where factor assay are 
not done systematically on patients with bleeding 
disorders attending these centres and fresh frozen 
plasma is used without knowing the concentration 
of coagulation factors it contains. This could lead to 
the circulatory overload without any improvement; 
if many bags are used with low level of factors. Also 
the education about coagulopathy management and 
prevention given by health workers in most health 
facilities in Rwanda is not specific to the bleeding 
disorders related to coagulation factors deficiency 
and is not based on some frequent characteristics 
and aetiologic causes of coagulopathy, this can lead 
to inappropriate management.  
 Data from this study was aimed at guiding 
the management of patients with factor deficiency 
and monitoring.  This study sheds light on level of 
fibrinogen, Factor II, Factor V, Factor VII, Factor VIII, 
Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, 
Antithrombin or Factor III, von WillbrandFactor, 
Protein C, and Protein S in current used plasmas which 
was remains elusive. The need for levels of coagulation 
factors data in donated blood were important in 
order to provide information on quality of fresh 
frozen plasma prepared by National and Regional 
Centres for Blood Transfusion. It has also served as 
basis to renew policies and procedures regarding 
storage conditions and quality control prior to clinical 
use of fresh frozen plasma.Rwanda has adopted a 
guidelines which have not been assessed using our 
population while coagulation factors level can vary 
depending on several conditions including race, age, 
blood groups and other environment condition. The 
results of this study offer an ideal storage temperature 
for coagulation factors in fresh frozen plasma after 
preparation in order to improve storage conditions. 
Through this study substantial data on coagulation 
factors have been given, it constitutes preliminary 
data for other related studies. 
MATERIALS AND METHODS
This descriptive study was conducted at 
Kigali, Butare and Ruhengeri Centres for Blood 
Transfusion and Kigali Health Institute at the 
Biomedical Laboratory Sciences, Haematology 
section. The sample population consisted of Fresh 
Plasma Bags from blood donors attending the centres 
for voluntary blood donation. Eighteen bags were 
sampled six from each centre enrolling in this study. 
A convenient sampling method has been used to get 
sample of this study.To determine level of coagulation 
factor level in FFP, seventy two samples of plasma 
have been collected from eighteen fresh plasma bags; 
four samples per each bag well prepared before 
freezing regardless blood groups, sex and age. Whole 
blood units (450±50 mL) have been collected in JMC 
triple bag containing 63 mL CPDA-1 and centrifuged 
within eight hours of collection and then a semi- 
automated extractor have been used to separate the 
plasma and put it in accessory blood bags and in four 
plain tubes 5ml in each, through a connecting device. 
Immediately after detachment from the main bag, 
the FFP bags and plain tubes frozen at minus 18ºC.
 After the agreement made between investigator 
and Kigali Health Institute collected samples taken 
to Kigali Health Institute, Biomedical Laboratory 
Sciences department, Haematology service, 
haemostasis section after collection, for Factor assay 
and APTT and PT tests. A cool box had been used 
in transportation of samples from National Centre 
for Blood Transfusion to Kigali Health Institute. 
After preparation before freezing, all samples were 
tested for HIV, Syphilis, hepatitis B and C, blood 
grouping and rhesus testing were done to ensure 
blood was safe to be given to another person.Only 
the first eighteen tubes were assayed for the level of 
coagulation factors and measurement of the APTT and 
PT before freezing or at baseline. The second assay 
was done on the second samples after one month, the 
sample was thawed by placement in a water bath at 
30–37 °C for 30 minutes then prepared for assays of 
the levels of coagulation factors and measurement 
of the APTT and PT, the third was done after two 
months and the last session was assayed after three 
months of storage. This means, we did four rounds 
of analysis in each round we assayed eighteen tubes 
of 5mls each from eighteen bags, the whole bag was 
not brought to Kigali Health Institute for analysis and 
taken back to National Centre for Blood Transfusion 
for donation.
 The coagulation factors have been assayed using 
a coagulation analyser named ACL 7000 a product of 
instrumentation Laboratory Company USA made in 
Italy, 2000 usingturbidmetric clot and chromogenic 
methods the same analyzer will be used to measure 
APTT and PT. This will provide reliable results by 
giving the exact amount of each coagulation factor in 
percentages, Prothrombin time and activated partial 
thrombin time in seconds. Two ways Anova was used 
and the P-value obtained from statistical tables was 
compared with the calculated value to get the effect 
of storage conditions (time and temperature) on the 
level of preserved fresh frozen plasma (P<0.05).
Ethical considerations: This study sought scientific 
approval from Rwanda Biomedical Centre division 
of Medical research committee, Ethical approval from 
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Rwanda National Ethics Committee, Research permit 
from Ministry of Education and Affiliation letter 
from National Centre for Blood Transfusion before 
excursion. Blood donors were informed about blood 
donation, blood product preparation, and the tests to 
be done on their samples, the risks and benefits of the 
research and need for their consent. The identity of the 
blood donors was treated with confidentiality. Results 
were sent to National Centre for Blood Transfusion 
management for them to know and to inform blood 
donors the level of their coagulation factors
RESULTS
 The level of coagulation factors and inhibitors were 
determined and analysed over time with a p-value 
< .005 (p < .005) findings reported with a p-value < 
.00325 (p < .00325) to avoid type one error; comparing 
baseline results and up to three months of storage 
based on both age, sex, weight and blood group 
of blood donors, we found significant decrease of 
fibrinogen (-10%), FII (-8%), FV (-15%), FVII (-13%), 
FX (-15%), FXIII (-5%), PC (-7%), and ATIII (-5%), 
show a decrease from baseline up to three months, 
whereas FVIII (-8%), F IX (-4%), FXI (-6%), FXII (-3%), 
FPS (-3%), and VWF-Ag (-7%) have been constant 
without significant change (+/-0%) from baseline 
to one month then changed also significantly over 
time and decreased up to three months. Prothrombin 
Time and Activated Partial Thrombin Time increased 
(0.5-1.5 second) from baseline up to one month of 
storage and from one month up to three months of 
storage had been stable.
Plot of coagulation factors levels in fresh frozen based on time point and sex
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These plots show estimated marginal means of APTT and PT expressed in seconds while in coagulation 
factors and inhibitors are expressed in percentages. Based on sex and time point as Independent variables, 
we found that APTT and PT increased from baseline up to one month of storage and became constant up 
to three months, instead fibrinogen, FII, FV, FVII, FX, FXIII, VWFAg, PC and ATIII show a decrease from 
baseline up to three months, while FVIII, FIX, FXI, FXII and FPS have been constant from baseline to one 
month then decrease up to three months.
Plot of coagulation factors levels in fresh frozen based on time point and blood group
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These plots show estimated marginal means of APTT and PT expressed in seconds while in coagulation 
factors and inhibitors are expressed in percentages. Based on blood group and time point these: APTT and 
PT show an increase from baseline to one month then remain constant up to three months, but: fibrinogen, 
FII, FV, FVII, FX, VWFAg, PC and ATIII have decreased from baseline up to three months and then FVIII, 
FIX, FXI, FXII and FPS remain constant from baseline up to one month and decreased up to three months.
Plot of coagulation factors levels in fresh frozen based on time point and age
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These plots show estimated marginal means of APTT and PT expressed in seconds while in coagulation 
factors and inhibitors are expressed in percentages. Based on Age and time point: APTT and PT show an 
increase from baseline to one month then remain constant up to three months, while; fibrinogen, FII, FV, 
FVII, FX, VWFAg, PC and ATIII have decreased from baseline up to three months and then FVIII, FIX, FXI, 
FXII and FPS remain constant from baseline up to one month and decreased up to three months.
Plot of coagulation factors levels in fresh frozen based on time point and weight
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These plots show estimated marginal means of APTT 
and PT expressed in seconds while in coagulation 
factors and inhibitors are expressed in percentages. 
Based on Weight and time point these: factors APTT 
and PT show an increase from baseline to one month 
then remain constant up to three months, whereas; 
fibrinogen, FII, FV, FVII, FX, VWFAg, PC and ATIII 
have decreased from baseline up to three months and 
then FVIII, FIX, FXI, FXII and FPS remain constant 
from baseline up to one month and decreased up to 
three months.
DISCUSSION
Fresh frozen plasma (FFP) is indicated for the 
treatment and prevention of bleeding disorders 
due to deficit in minor or major coagulation factors, 
defective management of massive bleedings, liver 
disease, disseminated intra-vascular coagulation or 
reverse anticoagulant therapy (2).
 According to United States of America and 
European guidelines for production of blood and 
blood product define Fresh Frozen Plasma (FFP) 
as the liquid portion of human blood that has been 
centrifuged, separated with blood cells, solid at minus 
18 degrees C or colder within eight hours of blood 
donation, and store up to three months contains all 
coagulation factors in normal concentration 0.5 to 
2IU/ml or (50-200%) to be used in blood transfusions 
(3).This study provides the first comprehensive 
analysis of the level of coagulation factors in fresh 
frozen in Rwanda.
 The reported results in this study on PT and 
APTT increase of 0.5-1.5 seconds from baseline up 
to three months is however prolonged than the time 
reported by Von Heymannet al., 2006 (4)which show 
an increase of 0.1-0.5 seconds, in their study titled 
“Coagulation parameters of thawed fresh-frozen 
plasma during storage at 1-6ºC for five days” in 
German and Thompson et al in Thailandin a study 
of coagulation factor activities in apheresed thawed 
fresh-frozen plasma at 1-6ºC for five days with an 
increase of 0.1-0.5 seconds.
 The level of coagulation factors and inhibitors 
were determined and analysed over time with a 
p-value < .005 (p < .005) findings reported with a 
p-value < .00325 (p < .00325) to avoid type one error; 
comparing baseline results and up to three months 
of storage based on both age, sex, weight and blood 
group of blood donors, we found significant decrease 
of fibrinogen (-10%), FII (-8%), FV (-15%), FVII (-13%), 
FX (-15%), FXIII (-5%), PC (-7%), and ATIII (-5%),  show 
a decrease from baseline up to three months,  whereas 
FVIII (-8%), F IX (-4%), FXI (-6%), FXII (-3%), FPS 
(-3%), and VWF-Ag (-7%) have been constantwithout 
significant change (+/-0%) from baseline to one 
month then changed also significantly over time and 
decreased up to three months.All clotting factors 
and inhibitors remained within the reference range 
requested by quality assurance regulations. This is 
compared to the results of a study done in German on 
Activity of clotting factors in FFP by Von Hermanny et 
al, immediately after thawing there was a significant 
decrease of fibrinogen (-9%), FII (-7%), FV (-14%), FVII 
(-12%), FX (-11%), FXIII (-20%), PC (-7%), and ATIII 
(-4%), while FVIII (+8%), F IX (+1%), FXI (+11%), 
FXII (-1%), FPS (-1%), and VWF-Ag (-6%) remained 
stable. Over 6 days after thawing fibrinogen, ATIII 
(+2%) and VWF-Ag (+2%) remained stable whereas 
FXII (+2%), FXIII (+6%), and PC (+3%) , FII (-8%), 
FV (-16%), FVII (-31%), FVIII (-47%), F IX (-12%), FX 
(-10%), FXI (-25%), and FPS (+/-0%).(5). The level of 
coagulation factors stated in my study is a bit different 
from the results of this study done in German, the 
variation in coagulation factors might have been 
caused by variation in temperature and number of 
days or time FFP has been stored. Mine were frozen 
at minus 18oC while Von Hermanny removed from 
freezer and kept them at 1-6ºC for six days. The 
decrease of coagulation factor level is normal for 
FFP kept for long time at high temperature; the more 
temperature is low the more you preserve enough 
level of coagulation factors. (AABB,2002), I did not 
found an increased level, more study are needed to 
provide information on the cause of increase in same 
coagulation factors level during storage as stated by 
von Hermanny.
 The current study’s results are a bit different 
compared to the results of another research done 
by Von Heymann et al., 2006 in German onThawing 
procedures and the time course of clotting factor 
activity in fresh frozen plasma, they have confirmed 
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a significant decrease of FVII (130% and 100%, p < 
0.001) and the relative stability of FVIII (150% and 
+/- 1%, p < 0.001), F IX (145% and +/- 1%, p < 0.001), 
FXI (130% and +/- 0%, p < 0.001), FXII (128% and 
+/- 1%), VWF-Ag (130% and +/- 1%, p < 0.001), 
and FPS (115% and +/- 0%, p < 0.001). Solely the 
decrease of fibrinogen (299 to 290 mg/dL, p < 0.001) 
and FV (130% and 116%, p < 0.001) which was not in 
accordance with their previous results, this showed 
an insignificant increase of both factors reported in 
their previous study (4).
 The reported decrease of coagulation factors 
level in this study is however lower than the 
decrease reported by Mark H. et all in America on 
Coagulation factor levels in plasma frozen within 
24 hours of phlebotomy over 5 days of storage at 1 
to 6°C, including FV, FVII and FVIII activity, which 
decreased by 40%, 20% and 50% respectively on Day 
5, the activity of PS was at the low end of the normal 
range and it declined to slightly below its normal level 
by Day 5. vWF activity remained within its normal 
range by Day 5.(6).The facts that the findings of this 
study are different from ours temperature and frozen 
time after phlebotomy, may have contributed to the 
observed variation.
CONCLUSION
Our results demonstrate that there is good retention 
of all coagulation factors and inhibitors in plasma 
produced from whole blood within eight hours of 
collection, stored at minus 18 ºC for three months and 
that such plasma would be an optional useful product 
for most patients with minor to major coagulation 
factor deficits to prevent blood loss. Moreover, this 
plasma will be used in treatment of disseminated 
intra-vascular coagulation, liver disease patients and 
reversal of therapy with vitamin K antagonists(8). 
Especially in emergency situations, transfusion of 
this plasma will deliver clotting factors without 
aggravating existing delusional coagulopathy 
induced by crystalloid or colloid volume replacement 
solutions (9).
 Recommendation:It is recommended that to 
measure at least labile factors before providing fresh 
frozen plasma preserved for more than three months. 
Prothrombin time and activated partial thrombin time 
might be included in pre-transfusion test to evaluate 
the activity of intrinsic and extrinsic coagulation 
factors in fresh frozen plasma before use. Whereas 
the findings of this study seem to suggest that Fresh 
Frozen Plasma might be store at minus 18ºC  for three 
months, for better management of bleeding disorders 
that need transfusion of Fresh Frozen Plasma.
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